The authors investigated the effe~t! of thymidylatẽ ;rJs ynthetase (TS) on the antivari~ella-zoster virus (VZV) activity of (E)-S-(2-bromovinyl)-2'-deoxyuridine (BVDU). TS catalyses the conversion of deoxyuridylate (dUMP) to thymidylate (dTMP) and is a key enzyme in pyrimidine biosynthesis, providing the only source of dTMP synthesized de novo in mammalian cells. VZV encodes a specialized viral form of TS. TS activity in cells infected with VZV (TK+-VZV and TK--VZV) increased proportionally with focus formation. From kinetic analysis using the Michaelis-Menten equation, the authors determined a K m value of 6.6!1M for dUMP of TS induced in VZV-infected cells and a corresponding value from mock-infected cells of only 2.8!1M. BVDU inhibited the induction of TS activity in TK+-VZV-infected cells at concentrations under x10-3 !1M, but did not inhibit TS activity of TK--VZV-or mock-infected cells at concentrations as high as 10!1M. Inhibitory activity of BVDU against TS induced in TK+-VZV-infected cells appears to occur when BVDU is phosphorylated to BVDU rnonophosphate by viral pyrimidine kinase. These results suggest that the selective inhibitory action of BVDU on VZV replication depends on a specific interaction with both viral TK and TS. S-Bromodeoxyuridine and S-iododeoxyuridine inhibited TS activities induced in both VZV (TK+, TK-) and mock-infected cells. Other antiherpes compounds [i.e. 1-~-D-arabinofuranosyl E-S-(2-bromovinyl)uracil, 9-(2-hydroxyethoxymethyl)guanine, arabinosyladenine, and others] did not
inhibit TS activity in VZV-infected cells at concentrations of 10!1 M.
The growth of herpesviruses requires nucleotide pools in infected cells, especially pools of deoxynucleotide triphosphates. Herpesviruses have several enzymes active in nucleotide metabolism to ensure the maintenance of adequate nucleotide pools. These include deoxythymidine kinase (TK), deoxyuridine triphosphatase, ribonucleotide reductase, uracil-DNA glycosylase, exonuclease, and DNA polymerase. These virus-induced enzymes are significantly different from their cellular counterparts in many of their properties and thus are key targets for selective antiviral chemotherapy. Recent studies revealing the preferential phosphorylation of several nucleoside analogues by the herpesvirus-induced TK marked a significant step forward in the development of antiviral chemotherapy. Examples of such analogues include 9-(2-hydroxyethoxymethyl)guanine (ACV), 1-~-D-arabino furanosyl-E-5-(2-bromovinyl)uracil (BVaraU) and 9-(2hydroxyethoxymethyl)guanine (BVDU). Both BVaraU and BVDU are highly potent and selective agents against the varicella-zoster virus (De Clercq et al., 1979; Machida et al., 1981) and are phosphorylated preferentially by virusinduced thymidine kinase (Yokota et al(1984 (Yokota et al( , 1987 (Yokota et al( , 1989 . Another virus-induced enzyme, thymidylate synthetase (TS), catalyses the conversion of deoxyuridylate (dUMP) to thymidylate (dTMP). Among human herpesviruses, VZV is the only one that encodes a TS gene (Davison et al., 1986; Thompson et al., 1987) . TS is a key enzyme in pyrimidine biosynthesis, providing the only source of dTMP synthesized de novo in mammalian cells (Cheng et al., 1983) . Therefore, TS activity induced by VZV may be involved in the antiviral mechanism of action of nucleoside analogues in VZV-infected cells.
In the study described here, the authors investigated the inhibitory activity of BVDU and other nucleoside analogues on TS activity induced in both TK+-and TK--VZVinfected cells.
Human embryonic fibroblast (HEF) cells were used to grow VZV and herpes-simplex virus type 1 (HSV-1, strain KOS ). Human diploid embryonic lung fibroblast (MRC-5) Corporation, Japan). The authors obtained 9-(2-hydroxyethoxymethyl) guanine (ACV) from Burroughs Wellcome Co. (Osaka, Japan). Other compounds, namely arabinosyladenine (AraA), arabinosylcytidine (AraC), arabinosylthymine (AraT), IOU, and BOU, were purchased commercially from Sigma Chemical Co. (St. Louis, MO).
Virus-infected cells were used to measure TS activity, as described previously (Yalowich et al., 1985) . Tubes were filled with 100 III aliquots of the cell suspension (10 7 cells mr" of MEM) and 50 III of drugs diluted with MEM.
After a 30-min preincubation period at 37°C using a shaking water bath in the presence or absence of drugs, 50 III of [5-3H]dUMP (20 IlM 50 ul") were added and incubation was allowed to proceed for an additional 30 min, unless stated otherwise. The reaction was terminated by transferring 100-1l1 aliquots of each tube into 0.5 ml centrifuge tubes containing 100 III of a 15% activated charcoal suspension in 4% aqueous perchoric acid. The tubes were stirred vigorously by vortexing, incubated for 10 min at 4°C, and centrifuged for 5 min in a Hitachi Microcentrifuge. The radioactivity of a 50 III aliquot of the supernatant fraction from each tube was counted in a liquid-scintillation spectrometer using a toluene-based scintillation mixture. Blank tubes, containing medium only, were included in the experiments and generally gave background counts of less than 1% of the total radioactivity (5 x 10 5 -2 x 10 6 dpm) added to the other tubes. All values obtained were corrected for background counts. The 50% effective dose (E0 5 0 ) values, determined from dose-reponse curves, represent the inhibitor concentrations required to inhibit the release of tritium by 50%. All experiments were repeated at least twice on separate days. Experimental data are reported as average values of the results of three independent determinations.
TS activity in VZV (TK+-VZV, TK--NZV)-infected cells increased proportionally with focus formation (Fig. 1 ). TS activity did not increase in mock-infected cells. TS activity was presumably induced in TK--VZV-infected cells to a greater extent than in TK+-VZV-infected cells. This is because dTMP has to be synthesized de novo in TK--VZV-infected cells, rather than be salvaged by viral TK as in the TK+-VZV-infected cells. However, no significant difference was found between the induction of TS activity in cells infected with TK+-VZVand those infected with TK--VZV. As shown in Fig. 1 , TS activity also increased proportionally with viral growth in HCMV-infected cells. TS activity in HSV-1-infected cells, however, increased transiently at an early stage of viral growth and then dropped sharply. The difference in TS induction among herpesviruses should be reflected by variations in pyrimidine nucleotide metabolism among virus-infected cells. TS activity is essential for maintaining the dTMP pools needed for viral DNA replication in HCMV-infected cells, as TK activity does not increase in cells infected with cells were used to grow human cytomegalovirus (HCMV, strain A0169). The cells were grown in Oulbecco's modified minimum-essential medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin G, and 100 Ilg/ml streptomycin. For viral infection, maintenance medium was as above but with the concentration of fetal bovine serum reduced to 2%.
The parent strain of VZV (Kanno, TK+-VZV), which had been isolated from a patient with herpes zoster, was cloned in HEF cells and passaged in HEF cultures. A mutant strain (Kanno-Kohmura, TK--VZV) , resistant to BVOU and BVaraU, was isolated by repeated passage of the parent VZV strain in the presence of 5-bromodeoxyuridine (BOU) and 5-iododeoxyuridine (IOU). Details of the isolation procedures used to obtain the TK--VZV strain are described in the authors' previous report (Yokota et el., 1984) . Cell-associated viruses, obtained from HEF cell monolayers infected with VZV, were used throughout.
[5-3H]dUMP (specific activity, 15 mCi mM-i ) was obtained from Amersham Japan Co. (Tokyo, Japan). BVOU and IVOU were kindly provided by Dr E. De Clercq (Katholieke Universiteit, Leuven, Belgium). Acyclic nucleoside phosphonate analogues were provided by Dr A. Holy (Institute of Organic Chemistry and Biochemistry, Prague, Czechoslovakia). BVaraU and dideoxynucleosides were provided by Dr H. Machida (Yamasa Shoyu ited TS activity induced in TK+VZV-infected cells at concentrations under 1xi 0-3 J.l.M, but did not inhibit TS activity of TK-VZV-, HCMV-, and mock-infected cells at concentrations up to 10 J.l.M as shown in Fig. 2 . BVOU is taken up only by TK+-VZV-infected cells (Yokota et al., 1984) . The incorporated BVOU is phosphorylated immediately to a monophosphate derivative (Yokota et al., 1987) . Therefore, the inhibitory activity of BVOU against TS induced in TK+VZV-infected cells seems to appear when BVOU is phosphorylated to BVOU monophosphate (BVOUMP) by viral pyrimidine kinase. A TS enzyme solution was prepared from crude extracts of TK""-VZV-infected cells. Since enzyme solutions prepared in this manner are free from viral TK activity, BVOU cannot be phosphorylated to BVOUMP. BVOU did not inhibit TS activity in this crude enzyme solution. Thus, BVOUMP inhibited de novo dTMP synthesis by direct competition with dUMP or through feedback inhibition. These results suggest that the selective inhibitory action of BVOU on VZV replication depends on a specific interaction with both viral TK and viral TS. On the other hand, BVaraU, which is a highly selective compound against VZV, did not inhibit TS activity at concentrations of 100 J.l.M, although this compound also is incorporated into TK+-VZV-infected cells and then phosphorylated to BVaraU monophosphate. BOU and IOU inhibited TS activity in both VZV (TK+, TK-) and mock-infected cells at concentrations of 0.1 to 10 J.l.M. The selective antiviral activity of these compounds against VZV is low, although they are taken up into mock-infected cells and phosphorylated by both cellular TK and viral TK. Therefore, it appears that BOU monophosphate and IOU monophosphate may inhibit TS activity. Other antiherpes compounds, ACV, AraA, AraC, AraT, acyclic nucleoside phosphonate analogues (HPMPA, PMEA, and HPMPC), and dideoxynucleosides (ddA, ddC, and ddT) did not inhibit TS activity in VZV-infected cells at 10 J.l.M. Thus, TS has highly specific interactions with particular nucleotide analogues.
In conclusion, BVOU inhibited viral TS activity induced in TK+-VZV-infected cells. The inhibition of TS activity in VZV-infected cells is an important component of the antiviral activity of BVOU against VZV. The selective inhibitory action of BVOU against VZV replication depends ona specific interaction with both viral TK and TS.
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